Calidi Biotherapeutics, Inc. financial data

Symbol
CLDI on NYSE, CLDWW on OTC
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152% % 652%
Debt-to-equity 199% %
Return On Equity -432% % -282%
Return On Assets -152% % 56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7,167,721 shares -45%
Common Stock, Shares, Outstanding 6,906,312 shares -26%
Entity Public Float $14,010,268 USD -68%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 4,907 shares
Weighted Average Number of Shares Outstanding, Diluted 4,907 shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $9,194,000 USD -17%
Operating Income (Loss) $19,800,000 USD 28%
Nonoperating Income (Expense) $332,000 USD -126%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $20,132,000 USD 23%
Income Tax Expense (Benefit) $20,000 USD 150%
Net Income (Loss) Attributable to Parent $20,023,000 USD 24%
Earnings Per Share, Basic 19 USD/shares 71%
Earnings Per Share, Diluted 19 USD/shares 71%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $9,600,000 USD
Assets, Current $11,028,000 USD 397%
Property, Plant and Equipment, Net $849,000 USD -14%
Operating Lease, Right-of-Use Asset $2,012,000 USD -38%
Other Assets, Noncurrent $140,000 USD -35%
Assets $14,029,000 USD 111%
Liabilities, Current $5,193,000 USD -55%
Operating Lease, Liability, Noncurrent $640,000 USD -70%
Liabilities $6,831,000 USD -58%
Accumulated Other Comprehensive Income (Loss), Net of Tax $13,000 USD 82%
Retained Earnings (Accumulated Deficit) $137,565,000 USD -17%
Stockholders' Equity Attributable to Parent $6,918,000 USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $7,198,000 USD
Liabilities and Equity $14,029,000 USD 111%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,131,000 USD -86%
Net Cash Provided by (Used in) Financing Activities $8,108,000 USD 169%
Net Cash Provided by (Used in) Investing Activities $7,000 USD -40%
Common Stock, Shares Authorized 330,000,000 shares 0%
Common Stock, Shares, Issued 6,906,312 shares -26%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $970,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,594,000 USD 401%
Interest Paid, Excluding Capitalized Interest, Operating Activities $639,000 USD 2562%
Deferred Tax Assets, Valuation Allowance $29,402,000 USD 23%
Deferred Tax Assets, Gross $30,232,000 USD 21%
Operating Lease, Liability $1,994,000 USD -40%
Depreciation $391,000 USD -2.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $19,886,000 USD 25%
Lessee, Operating Lease, Liability, to be Paid $2,178,000 USD -43%
Property, Plant and Equipment, Gross $2,561,000 USD 12%
Operating Lease, Liability, Current $1,354,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year Two $295,000 USD -80%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,512,000 USD 6%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $184,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,000 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards $20,221,000 USD 33%
Unrecognized Tax Benefits $1,799,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,000 USD -100%
Operating Lease, Payments $362,000 USD 3.7%
Additional Paid in Capital $144,495,000 USD 35%
Share-based Payment Arrangement, Expense $2,285,000 USD -35%